CathVision Cube: disruptive data-driven guidance for successful cardiac ablation therapy
Sector: Hospital • Location: Denmark
Source: EU Funding & Tenders Portal
Cardiac arrhythmias are projected to rise during next years. The most prevalent type, Atrial Fibrillation, is projected to increase in the EU from 8.8m in 2010 to 17.9m by the year 2060, leading to a strain on physicians and health systems. Thus, better ablation guiding tools will be necessary to help physicians more efficiently identify, characterise and treat arrhythmias, facilitating training o
Project Information FAQ
Project Information
Want to explore the full details? View the full report
Participants
Sponsoring Agency | Obfuscated Data |
Company | Obfuscated Data |
Status
Original status | ended |
Taiyo status | Obfuscated Data |
Taiyo last update | 00-00-0000 |
Available timestamps | 00-00-0000 |
Available timestamp type | Obfuscated Data |
Contact
Contact name | Obfuscated Data |
Phone | 0000000000 |
ObfuscatedData@email.com | |
Address | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Description
Description | Cardiac arrhythmias are projected to rise during next years. The most prevalent type, Atrial Fibrillation, is projected to increase in the EU from 8.8m in 2010 to 17.9m by the year 2060, leading to a strain on physicians and health systems. Thus, better ablation guiding tools will be necessary to help physicians more efficiently identify, characterise and treat arrhythmias, facilitating training of new electrophysiologists, while reducing procedure and medicine costs. Sex-specific CVD also needs to be better addressed, as it is currently often misdiagnosed in females due to smaller cardiac signals and standards based on male physiology. CathVision Cube is a low-noise electrophysiology (EP) recording system that combines a cutting-edge amplifier with AI assisted decision-making and easy-to-use user interface. Physicians will have access to exceptional EP signals thanks to proprietary hardware technology that reduces noise, prevents signal artefacts and improves signal quality. Doctors will also gain electrogram-driven clinical decision support through the intuitive and logical graphical interface of our AI-software, which allows proper identification of arrhythmogenic areas and guidance to a successful ablation – particularly important for less experienced EP physicians. Moreover, our system enables data export to Electronic Medical Records (EMR), integrates seamlessly into the hospital environment and is also compatible with third-party equipment. Our goal is to mature, pilot and commercialise our CathVision Cube – the world first low-noise EP recording system and AI-assisted decision-making for physicians performing cardiac ablation therapy. A successful CathVision Cube project will create measurable impacts on our company, quantified as accumulated revenue of €457m in 5 years (2021-2025), accumulated operating profit of €348m, creating 45 FTE in our value chain, generating €1.35m in reduced annual costs per hospital and unlocking public savings of €1.1bn by 2025 |
Original sub-sector | Obfuscated |
Original Currency | USD |
Original budget | 000000000000000 |
Procurement method | Obfuscated Data |
Budget | 000000000000000 |
Location
Region | Obfuscated |
Country | Obfuscated |
State | Obfuscated Data |
County | Obfuscated |
Location | Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data |
Source
Source reliability | High |
Data quality score | 100% |
Source | Obfuscated Data |
URL | obfuscated_data,obfuscateddata.com |
More Details
Project Type | Obfuscated Data |
Article Published Date | Obfuscated Data |
